CORONA Remedies Q1 FY27 Earnings Call Transcript Released
CORONA Remedies reported Q1 FY27 revenue of ₹422 Cr, up 21.9% YoY. EBITDA grew 33.5% to ₹93 Cr, and PAT increased 30.1% to ₹60 Cr. The company outperformed the IPM with 22.7% India business growth. Management reaffirmed FY27 guidance of 15% organic revenue growth and 20% PAT growth.
The announcement details significant financial performance exceeding expectations, strategic advancements in manufacturing capabilities, and a strong market position. This information is material for investors and stakeholders, influencing investment decisions and market perception.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, exceeding its own guidance and outperforming the market. The successful commercialization of a new manufacturing facility and positive market outlook contribute to the positive sentiment.
CORONA Remedies Limited has released the transcript of its Earnings Conference Call held on August 3, 2026. The call focused on the financial results for the first quarter and three months ended June 30, 2026.
During the call, the management highlighted that the Indian Pharmaceutical Market (IPM) is experiencing robust growth, exceeding 10% since December 2025. CORONA Remedies has outperformed the market, becoming the fastest-growing pharmaceutical company among the top 30, improving its ranking to 26th. The company reported a 21.9% year-on-year revenue growth in Q1 FY27, surpassing its guidance of 15%. The India business saw an impressive 22.7% year-on-year growth, nearly double the IPM's growth rate.
The growth was attributed to a healthy product mix, including volume growth (6.3% vs. IPM's 1.3%), new introductions (3.4% vs. IPM's 2.9%), and price growth (8.7% vs. IPM's 5.6%). CORONA operates in four key therapeutic areas: Women’s Healthcare, Cardio-metabolic, Pain Management, and Urology, holding strong leadership positions in these segments. The company also announced the successful commercialization of its advanced Europe-GMP approved Women’s hormone manufacturing facility and the renewal of its Europe-GMP certification for its Ahmedabad oral solid dosage form facility.
Financially, revenue for Q1 FY27 stood at ₹422 crores, a 21.9% increase year-on-year. EBITDA grew by 33.5% to ₹93 crores, with EBITDA margins improving to 22%. Profit After Tax (PAT) was ₹60 crores, a 30.1% increase year-on-year, with PAT margins at 14.2%.
The management reiterated its guidance of 15% organic revenue growth and 20% PAT growth for FY27. They also discussed the strategic focus on India's business, the integration of acquired brands like Wokadine, and investments in R&D to strengthen the innovation pipeline.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.